- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07940387
IV Lidocaine in Ortho Trauma Patients
The Efficacy of Perioperative Intravenous Lidocaine as an Opioid Sparing Adjunct for Patients Undergoing Lower Extremity Orthopedic Trauma Surgery
In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- 모병
- Detroit Receiving Hospital
-
연락하다:
- Jessica Phillips, PhD, CRNA
- 전화번호: 313-577-9239
- 이메일: fy9015@wayne.edu
-
연락하다:
- Mary Golinski, PhD, CRNA
- 전화번호: 248 364 8776
- 이메일: golinski@oakland.edu
-
수석 연구원:
- Jessica Phillips, PhD, CRNA
-
수석 연구원:
- Mary Golinski, PhD, CRNA
-
수석 연구원:
- Wael Saasouh, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- ASA physical status I-III, males and females >18 years of age and < 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.
Exclusion Criteria:
- Contraindication to lidocaine including allergy, substantial hepatic impairment (alanine aminotransferase greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac ejection fraction less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.
Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of <95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Control Group - Saline Infusion
Saline bolus and infusion |
Saline infusion |
|
실험적: Intervention - IV Lidocaine Group
Lidocaine bolus and infusion |
A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Morphine equivalents
기간: from enrollment to 14 days postoperative
|
Amount of opioids in morphine milligram equivalents (MME) used in 2 weeks/14 days postoperative period |
from enrollment to 14 days postoperative
|
|
Interleukin 6 (IL-6)
기간: 1, 6, 24 and 48 hours postoperative
|
Interleukin 6 (IL-6) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Interleukin 8 (IL-8)
기간: 1, 6, 24 and 48 hours postoperative
|
Interleukin 8 (IL-8) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Complement C3a
기간: 1, 6, 24 and 48 hours postoperative
|
Complement C3a present in serum plasma at 1, 6, 24 and 48 hours postoperative in ng/mL |
1, 6, 24 and 48 hours postoperative
|
|
Visual Analogue Pain Score
기간: Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
Visual Analogue Pain Score with 0 = no pain and 10 = worst pain ever. |
Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quantitative Sensory Testing
기간: Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
Mechanical and thermal pain thresholds will be measured adjacent to the incision site to measure hyperalgesia |
Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- IRB 24-11-7305
- 2025-G-5 (기타 보조금/기금 번호: AANA Foundation)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Any information containing patient information or protected health information (PHI) such as master list documents containing patient names and medical record numbers will be stored securely in a locked office inside a locked filing cabinet at the DMC site. All other data will use a subject number assigned and remove all 18 types of PHI information De-identified and be hard copies (paper records) will also be stored securely in a locked office inside a locked filing cabinet. DMC collected data will be saved on the DMC secure server in the Citrix platform. Study data will only be accessible to investigators involved in the study. Statistical analysis will be performed on de-identified encrypted digital data.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .